Novacyt

Board/Management Information • Jun 20, 2025

National Storage Mechanism | Additional information

RNS Number : 6675N

Novacyt S.A.

20 June 2025

Novacyt S.A.

("Novacyt", the "Company" or the "Group")                                                  

Result of AGM

Paris, France, and Manchester, UK - 20 June 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the results of voting on the resolutions at its Annual General Meeting ('AGM'), held yesterday, as set out in the Notice of AGM.

All Ordinary Resolutions presented at the Ordinary General Meeting were passed and Resolutions 10, 11, 15, 20, 22 and 24 were passed from the Extraordinary General Meeting. Full details of the results of the AGM voting are available on the Company's website and a recording of the AGM will be made available shortly - https://novacyt.com/investors/general-meetings/

Lyn Rees, CEO of Novacyt, said: " Yesterday's vote marks a positive step forward, giving the Board enhanced flexibility to respond to opportunities in an increasingly dynamic and competitive marketplace. Our focus remains on delivering sustainable, long-term value through a disciplined organic growth strategy. This is being underpinned by targeted cost base rationalisation and executed through our newly established Centre of Operational Excellence, alongside continued investment in our high potential new product pipeline.

The approval of key financial resolutions positions the Company to act decisively on accretive opportunities as they arise. While certain initiatives may require further support from existing shareholders, they will be pursued with a clear focus on driving shareholder value."

Contacts

Novacyt SA			https://novacyt.com/investors
Lyn Rees, Chief Executive Officer			Via Walbrook PR
Steve Gibson, Chief Financial Officer
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)				+44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
Deutsche Numis (Joint Broker)				+44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Michael Palser
Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit		+33 (1) 42 22 10 10 [email protected] / [email protected]
Walbrook PR (Financial PR & IR) Paul McManus / Lianne Applegarth Alice Woodings			+44 (0)20 7933 8780 or [email protected] +44 (0)7980 541 893 / +44 (0)7584 391 303  +44 (0)7407 804 654

About Novacyt Group ( www.novacyt.com )

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical	Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests ·    Precision Medicine: DPYD genotyping assay ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation	Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: ·    Ranger® Technology: automated DNA sample preparation and target enrichment technology ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only	Range of services for the life sciences industry: ·    Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry ·    Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGKKLFFEQLEBBV